Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Barinthus Biotherapeutics PLC Sponsored ADR is a member of the Medical sector. This group includes 918 individual stocks and currently holds a Zacks Sector Rank of #10. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Barinthus Biotherapeutics PLC Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for BRNS' full-year earnings has moved 34.5% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, BRNS has gained about 8.4% so far this year. In comparison, Medical companies have returned an average of 4.4%. This means that Barinthus Biotherapeutics PLC Sponsored ADR is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, Agilent Technologies (A), has outperformed the sector so far this year. The stock's year-to-date return is 10.9%.
For Agilent Technologies, the consensus EPS estimate for the current year has increased 3.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Barinthus Biotherapeutics PLC Sponsored ADR is a member of the Medical - Biomedical and Genetics industry, which includes 439 individual companies and currently sits at #163 in the Zacks Industry Rank. On average, this group has gained an average of 10.1% so far this year, meaning that BRNS is slightly underperforming its industry in terms of year-to-date returns.
On the other hand, Agilent Technologies belongs to the Medical - Products industry. This 86-stock industry is currently ranked #92. The industry has moved -17.3% year to date.
Investors with an interest in Medical stocks should continue to track Barinthus Biotherapeutics PLC Sponsored ADR and Agilent Technologies. These stocks will be looking to continue their solid performance.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS): Free Stock Analysis Report
Agilent Technologies, Inc. (A): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).